CJC-1293
A modified GHRH analog similar to CJC-1295. Stimulates growth hormone release for research purposes.
Beginner Basics
Plain-English guide to CJC-1293
What it does
CJC-1293 signals your body to release more growth hormone, which researchers study for its potential to support muscle building, fat loss, and recovery from exercise.
Typical dose
Researchers typically use 100-200 mcg injected under the skin once daily, though some protocols go up to 300 mcg daily split into multiple injections.
When to inject
Common timing is before bed, before meals, or after exercise, though the best time depends on your individual response.
Storage
Keep the dry powder frozen at -20°C until you mix it. Once mixed with liquid, store it in the refrigerator between 2-8°C and keep it away from light.
First-timer tip
Start with the lowest dose (100 mcg once daily) for at least a week to see how your body responds before increasing the amount.
On This Page
Research Status
Early Research
For research purposes only. Not approved for human use. Not medical advice.
Research Areas
Side Effects
Erythema, mild swelling, or discomfort at the injection site typically resolves within 24 hours. Rotate injection sites to minimize local irritation. Apply ice if swelling persists.
Transient flushing may occur within 15-30 minutes of injection due to GH-mediated vasodilation. Usually self-resolving within 30-60 minutes.
Mild headache has been reported in some research subjects. Typically mild and transient; consider hydration and rest. Discontinue if severe or persistent.
GH is diabetogenic and may impair insulin sensitivity or elevate fasting glucose, particularly at higher doses or in predisposed individuals. Monitor fasting glucose and HbA1c; discontinue if clinically significant hyperglycemia develops.
Prolonged GH elevation may cause fluid retention and nerve compression in the carpal tunnel. Symptoms include wrist pain, numbness, or tingling. Seek medical evaluation if symptoms develop.
Myalgia or arthralgias have been reported in some users, possibly related to rapid changes in GH or IGF-1 levels. Usually mild and self-resolving; consider dose reduction if severe.
GH promotes sodium and water retention, potentially causing mild peripheral edema or weight gain. Typically mild and reversible upon discontinuation.
Repeated injections at the same site may cause localized fat loss (lipoatrophy) or fat thickening (lipohypertrophy). Strict site rotation prevents this complication.
Mild nausea has been reported in some research subjects. Usually transient and self-resolving; consider taking the injection with food if nausea occurs.
Transient dizziness may occur immediately after injection. Sit or lie down if this occurs; symptoms typically resolve within minutes.
Dosing Reference
| Parameter | Value |
|---|---|
| Dose range | 100-300 mcg |
Frequency, timing and route - members only | |
Research disclaimer
Figures drawn from published research literature and community logs. Not clinical recommendations. Consult a qualified professional. Research use only.
Reconstitution Guide
Do not use saline or bacteriostatic saline, use only bacteriostatic water for reconstitution
Do not shake the vial vigorously; gentle swirling prevents peptide degradation
Discard immediately if the solution appears cloudy, discolored, or contains visible particles
Use within 30 days of reconstitution when stored at 2-8°C
Do not freeze the reconstituted solution; freezing may denature the peptide
Use the PeptideVolt reconstitution calculator for your exact concentration
Molecular and Pharmacological Data
| Half-life | Approximately 7-10 days (extended compared to native GHRH, which has a half-life of 2-4 minutes) |
CJC-1293 is a synthetic analog of growth hormone-releasing hormone (GHRH) that binds to GHRH receptors on somatotroph cells in the anterior pituitary gland. This binding stimulates the synthesis and secretion of growth hormone (GH), which in turn promotes the hepatic production of insulin-like growth factor-1 (IGF-1). The extended half-life of CJC-1293 (compared to native GHRH) results from modifications that enhance resistance to enzymatic degradation, allowing for less frequent dosing while maintaining sustained GH and IGF-1 elevation.
Track your CJC-1293 research
Free account. No credit card required.
Recent Research
Online large volume sample staking preconcentration and separation of enantiomeric GHRH analogs by capillary electrophoresis.
Qualitative identification of growth hormone-releasing hormones in human plasma by means of immunoaffinity purification and LC-HRMS/MS.
Expanded test method for peptides >2 kDa employing immunoaffinity purification and LC-HRMS/MS.
Source: PubMed / NCBI. Updated daily. Articles are listed for research reference only.
Browse the Research Library
40+ peptide profiles with mechanism summaries, dosing data, and reconstitution guides.
View all peptidesResearch Use Only. All content on this page is provided for informational and educational purposes related to scientific research. CJC-1293 is not approved for human use by the FDA or any equivalent regulatory body. This is not medical advice. Do not use any substance discussed here for therapeutic, diagnostic, or preventative purposes. Consult a qualified healthcare professional before making any health-related decisions. The Peptide Volt does not endorse the use of any research chemicals. 18+ only.